Skip to main content

Table 1 Patients and transplant characteristics

From: Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data

Characteristics

HID

MSD

p

No. of patients

119

132

–

Median age, years (range)

28 (14–54)

33 (16–56)

.127

Sex, no. (%)

  

.448

 Male/female

65 (54.6)/54 (45.4)

65 (49.2)/67 (50.8)

 

Underlying diseases, (%)

  

.731

 AML

54 (45.4)

57 (43.2)

 

 ALL

55 (46.2)

60 (45.4)

 

 ALAL

10 (8.4)

15 (11.4)

 

Disease stage at transplants, (%)

  

.447

 Primary induction failure

58 (48.7)

57 (43.2)

 

 Relapse refractory

61 (51.3)

75 (56.8)

 

WBC count at diagnosis, n (%)

  

.615

 ≥ 30,000 per mm3

57 (47.9)

59 (44.7)

 

 < 30,000 per mm3

62 (52.1)

73 (55.3)

 

Median BM blasts before conditioning (range)

33% (7.0–96.0%)

31% (8.0–98.0%)

.602

Genetics, (%)

  

.527

 Poor

65 (54.6)

66 (50.0)

 

 Intermediate

34 (28.6)

45 (34.1)

 

 Favorable

5 (4.2)

8 (6.1)

 

 Unknown

15 (12.6)

13 (9.8)

 

Graft no. (%)

  

-

 BM + PBSC

119 (100)

3 (2.3)

 

 PBSC

0 (0)

129 (97.7)

 

Median MNCs, 108/kg (range)

7.36 (3.76–12.80)

7.80 (3.52–13.16)

.136

MedianCD34 + count, 106/kg (range)

5.65 (1.15–15.16)

5.41 (0.98–16.46)

.471

Follow-up time in survivors from transplant, median (range), mouth

43.4 (20.5–71.5)

41.6 (18.2–72.7)

.814

  1. AML acute myelogenous leukemia, ALL acute lymphoblastic leukemia, ALAL acute leukemia of ambiguous lineage, MNC mononuclear cell, PBSC peripheral blood stem cell, BM bone marrow